好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Diagnosis and Treatment of Epilepsy in Patients with Multiple Sclerosis: a Case Series from Argentina
Multiple Sclerosis
P17 - Poster Session 17 (11:45 AM-12:45 PM)
12-010

The aims of this study were: to describe the clinical characteristics and brain images of patients with Multiple Sclerosis (MS) who presented seizures attributable to this entity, and to determine risk factors for recurrence of seizures in this population. 

Seizures are an atypical presentation form of MS. However, the prevalence of epilepsy in MS patients is more frequent than in the general population. Current data comes mainly from case series and there is little information in Latin-American populations.

Retrospective review of clinical records from adult MS patients evaluated between January/2011 and July/2021, at a tertiary center who had presented at least one seizure without other causes than MS. Demographic features, clinical characteristics, ancillary methods, and response to antiepileptic drugs (AED) were analyzed. A logistic regression analysis was performed to assess risk of seizure recurrence.

Out of 1277 patients who met criteria for MS diagnosis, 23 were included (female n=17). Prevalence of epilepsy due to MS was 1.8%. Median age at MS diagnosis was 30 years-old. Fifteen patients had RRMS (65%), 6 SPMS (26%), and 2 PPMS (9%). Median age at first seizure was 36.8 years. About 65% had focal seizure onset, and 30% presented a single episode. Eighty one percent received AED. Response to treatment resulted in seizure control in 96%, but 13% developed drug resistant epilepsy. Brain MRI showed that 35% of patients had cortical, and 82% juxtacortical lesions. No predictors of seizure recurrence were found.

This is the largest case series from Latin-America about MS patients with epilepsy. Our population was similar to other reported cohorts worldwide. In contrast, we observed a high percentage of patients who presented a good clinical response after treatment with AED. Further studies are necessary to determine seizure risk recurrence in this specific population.
Authors/Disclosures
Melanie Lara Sanchez, MD (FLENI)
PRESENTER
Dr. Sanchez has nothing to disclose.
Abril Marone, MD (Institute for Neurological Research Raul Carrea. Fleni) Dr. Marone has nothing to disclose.
Mariano Marrodan, MD (Institute for Neurological Research Raul Carrea. Fleni) Dr. Marrodan has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Marrodan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck, Astra Zeneca, Gador, Biogen, Roche and Novartis.
Jorge D. Correale, MD (Institute for Neurological Research) Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROche. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Correale has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Correale has received research support from Merck. The institution of Dr. Correale has received research support from Biogen. The institution of Dr. Correale has received research support from Novartis .